LATEST PRESS RELEASE
Amorfix provides update on ovarian cancer preclinical studies
June 05, 2013
Amorfix to investigate lung cancer misfolded proteins for therapeutic intervention
April 25, 2013
2013 BIO International Convention
April 22-25, 2013 : Chicago, IL, USA
American Association for Cancer Research
April 9, 2013 : Washington, DC, USA
Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing therapeutic products and diagnostic devices targeting misfolded protein diseases including ALS, cancer, and Alzheimer's Disease.
Amorfix is a pioneer in the ability to identify unique regions that are buried in normal proteins, and exposed to antibodies when proteins are aberrantly folded. These unique regions are designated Disease Specific Epitopes™ (DSE), which can be exploited by Amorfix to develop highly specific diagnostic tools, as well as targets for therapeutics of protein misfolding diseases.